Politician trade (Senate)

Boston Scientific (BSX): Sen. John Boozman disclosed a partial sale $1K–$15K

Sen. John Boozman disclosed a partial sale of Boston Scientific in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
27 days
Disclosure lag
Traded
Dec 17, 2025
Disclosed
Jan 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 17, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  2. Oct 22, 2025Company filing · Form 8-K · ResultsReported its results
  3. Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, John E. Sununu informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  4. Oct 27, 2025InsiderDirector sold ~$1.01M of BSX shares in the open market
  5. Oct 28, 2025InsiderDirector sold ~$297K of BSX shares in the open market
  6. Oct 28, 2025CongressDisclosed partial sale of BSX — reported range $15,001 - $50,000
  7. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  8. Oct 31, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  9. Nov 3, 2025Insider · 1 personInsiders: 3 sales (~$5.0M)
  10. Nov 6, 2025InsiderDirector sold ~$1.27M of BSX shares in the open market
  11. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2026 Annual Bonus Plan effective for the performance year of January 1, 2026 through December 31, 2026 (the “2026 Annual Bonus Plan”).”
  12. Nov 18, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  13. Dec 1, 2025InsiderOfficer sold ~$1.76M of BSX shares in the open market
  14. Dec 16, 2025Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  15. Dec 17, 2025 · this disclosureCongressDisclosed partial sale of BSX — reported range $1,001 - $15,000

What came next

  1. Dec 19, 2025FDARecall: HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 6mm x 8mm; Material Number (UPN): M00553520;
  2. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 20mm x 10mm; Material Number (UPN): M00553660;
  3. Dec 19, 2025FDARecall: *HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 20mm x 10mm; Material Number (UPN): M00553560;
  4. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 6mm x 8mm; Material Number (UPN): M00553680;
  5. Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  6. Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
  7. Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  8. Jan 23, 2026FDAFDA device clearance: BodyGuardian Remote Monitoring System (BGRMS v3.0)
  9. Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  10. Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  11. Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$15.0M)
  12. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  13. Feb 10, 2026FDAFDA device clearance: SpaceOAR Vue System (SV-2101)
  14. Feb 10, 2026FDARecall: EndoVive Safety PEG Kit; Outer Box Material Number (UPN): M00509001; Inner Box Material Number (UPN): M00509000;
  15. Feb 10, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  16. Feb 12, 2026Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  17. Feb 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of…”
  18. Feb 26, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
  19. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: In re: Boston Scientific Corporation Securities Litigation
  20. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: Troike v. Boston Scientific Corporation
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

Other recent filings by Sen. John Boozman

The full history of Sen. John Boozman is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Boston Scientific (BSX) stock, and how much?

Sen. John Boozman disclosed a partial sale of Boston Scientific in the $1K–$15K range. Reported range, not an exact amount, Joint account.

When did it happen, and when was it made public?

Traded: Dec 17, 2025. Disclosed: Jan 13, 2026. That is 27 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the Senate eFD periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Boston Scientific recently?

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.

Does this mean BSX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data